Neoadjuvant hormonal therapy in prostate cancer - impact of PSA level before radiotherapy

作者：Dolezel M^*; Odrazka K; Vanasek J; Vaculikova M; Vlkova Sefrova J; Jansa J; Macingova Z; Brodak M; Hartmann I; Melichar B

来源：Journal of Buon, 2013, 18(4): 949-953.

• androgen-deprivation therapy
• neoadjuvant hormonotherapy
• prostate cancer
• PSA
• radiotherapy

Purpose: To retrospectively investigate the impact of prostate specific antigen (PSA) level after neoadjuvant androgen-deprivation therapy (ADT) on biochemical relapse-free survival in patients with prostate cancer who received radical radiotherapy (RT).
Methods: Between March 2003 and March 2008, 128 men with localized prostate cancer underwent neoadjuvant ADT for 4-6 months followed by radical RT. Biochemical relapse-free survival was compared between patients with pre-RT PSA <= 0.1 vs > 0.1 ng/mL.
Results: At a median follow up of 47.3 months, biochemical relapse-free survival was significantly higher in patients with a pre-RT PSA <= 0.1 ng/mL compared with pre-RT PSA > 0.1 ng/mL (85.6 vs 63.2%, p = 0.0025).
Conclusion: The current analysis demonstrating better treatment outcome in patients with excellent biochemical response to neoadjuvant ADT, supports an individualized treatment strategy.

• 出版日期2013-12